Clinical Trial Update: A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA [Phase 3]

View source ↗

Summary

This clinical trial update notes that CS0159 is in Phase 3 testing for primary biliary cholangitis patients with inadequate response or intolerance to UDCA, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• CS0159

Snippet

Sponsor: Cascade Pharmaceuticals, Inc | Conditions: Primary Biliary Cholangitis | Phase 3 | Status: RECRUITING